RxDoctor Payments Data

Jaclyn Jankowski, DO

Orthopaedic Surgery · Jersey City, NJNPI 1225491483

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (37.3%), food and beverage and education — rather than concentrated in one kind of arrangement. Kerecis Limited accounts for 60.2% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $14,388, 6.2 times the $2,313 reported in 2021.

$32,853in general payments, 2019–2025

Across 130 payments — averaging $252.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$20K
  • Synthes USA Products LLC$6K
  • Arthrex$2K
  • Johnson & Johnson$2K
  • Stryker$1K
  • Zimmer Biomet$490
  • plus $2K from 21 others
$10,891in research payments, 2019–2025

Across 4 payments — averaging $2722.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Zimmer Biomet$11K

What the payments were for

  • Consulting fees$4,65014%
  • Speaking & faculty fees$12,25037%
  • Grants$4501%
  • Travel & lodging$3,98712%
  • Food & beverage$6,64220%
  • Education$4,87515%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,853 in reported general payments places this provider in the 85th percentile of 587 orthopaedic surgery providers in New Jersey.

See all orthopaedic surgery providers in New Jersey →

Medicare billing

Part B allowed, 2024
$181,543
Medicare patients
303
Services billed
2,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Potassium11$17,996
Diclofenac Sodium538$17,013
Gabapentin13$99
Meloxicam20$63
Tramadol Hcl17$49

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Jersey City

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →